CURE Media Group Opens Nominations for 2021 Lung Cancer Heroes® Awards Program
/PRNewswire/ — CURE Media Group the industry-leading multimedia platform devoted to cancer updates and research that reaches over 1 million patients,…
Related Articles
Invitae Enters into Agreement with Labcorp for Sale of Business
/PRNewswire/ — Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive…
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15…
IDTechEx Examines the Opportunities for Wearables in Digital Health
/PRNewswire/ — With every successive year, the lines between medical devices and consumer electronics become increasingly blurred – medtech companies seek to…
VieCure Streamlines Cancer Care by Adding E-Prescribing Solutions from DrFirst
/PRNewswire/ — VieCure, a cancer care company, today announced that it is integrating e-prescribing and medication management solutions from health technology…
16 Bit Announces FDA De Novo Marketing Authorization of Rho™, an AI-enabled Opportunistic Pre-Screen for Low Bone Mineral Density on Standard X-Rays
/PRNewswire/ – 16 Bit Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted a De Novo marketing authorization for Rho™, an…
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15…
Sira Medical Wins FDA Clearance for Augmented Reality Preoperative Surgical Planning Software
/PRNewswire/ — The U.S. Food and Drug Administration granted Sira Medical 510(k) clearance for its augmented reality preoperative surgical planning…
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease
/PRNewswire/ — Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to…
2024 Appian Innovation Award Winners Demonstrate Significant Business Results with Next-Gen AI Process Automation
/PRNewswire/ — Appian (Nasdaq: APPN) today announced the winners of the 2024 Appian Innovation Awards at its annual global conference, Appian World. Each…
